Vir Biotechnology, Inc. progresses HDV treatment with promising ECLIPSE program results. Click here to find out why VIR stock ...

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at ...

Unlike traditional fat burners that rely on caffeine or complicated routines, Flash Burn offers a simple ... is not a drug and does not mimic GLP-1 medications. Pricing starts at $69 for a ...

The global Burn Care Market is projected to be valued at USD 2.79 billion in 2024 and reach US$ 4.23 billion by 2030, growing ...

But the harsh reality is that very many loss making companies burn through all their cash and go bankrupt. So should CollPlant Biotechnologies (NASDAQ:CLGN) shareholders be worried about its cash burn ...

Unlike traditional fat burners that rely on caffeine or complicated routines, Flash Burn offers a simple ... alternative”, though it is not a drug and does not mimic GLP-1 medications. Pricing starts ...

Capricor's lead asset, deramiocel, targets DMD-related cardiomyopathy and faces key FDA milestones. Find out why CAPR stock ...

Shares of biotechnology company Prime Medicine, Inc. (PRME) fell 18% on Monday afternoon after the company announced a ...

T he cost of prescription drugs in the U.S. has long outpaced that of peer nations, a dynamic driven by a combination of ...

Having said that, unprofitable companies are risky because they could potentially burn through all their cash and become distressed. So should Spanish Mountain Gold (CVE:SPA) shareholders be worried ...

Unity Biotechnology and Mammoth Biosciences are ... from its phase 2b Aspire trial that weighed its investigational eye treatment UBX1325 against Regeneron’s blockbuster Eylea in patients ...

The cuts to three advanced drug programs were “inevitable” given the company’s “unsustainable cash burn,” one analyst wrote ...